Diseases /

Endometrial Adenocarcinoma

Back to Diseases List
Associated Genetic Biomarkers

Overview

NCI Definition: An adenocarcinoma arising from the uterine body cavity. This is the most frequent malignant tumor affecting the uterine body, and is linked to estrogen therapy. Most patients present with uterine bleeding and are over age 40 at the time of diagnosis. The prognosis depends on the stage of the tumor, the depth of the uterine wall invasion, and the histologic subtype. Endometrioid adenocarcinoma is the most frequently seen morphologic variant of endometrial adenocarcinoma. [1]

Biomarker-Directed Therapies

View Therapies for Endometrial Adenocarcinoma

Clinical Trials

View Clinical Trials for Endometrial Adenocarcinoma

Significant Genes in Endometrial Adenocarcinoma

BRCA1 +

BRCA2 +

ERBB2 +

POLE +

Disease Details

Synonyms
Metastatic adenocarcinoma, c/w endometrial primary, Adenocarcinoma c/w Endometrial Primary, UTERUS ENDOMETRIAL ADENOCARCINOMA (NOS), Adenocarcinoma of Endometrium, ADENOCARCINOMA, ENDOMETRIAL, MALIGNANT, Adenocarcinoma of the Endometrium, Adenocarcinoma c/w Uterine Primary
Parent(s)
Endometrial Carcinoma
Children
Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, and Endometrial Clear Cell Adenocarcinoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.